BW-20805 cut HAE attacks by 96% with 24-week dosing. What Argo’s Phase 2 data really show
Argo Biopharma’s updated Phase 2 data show up to a 96% reduction in hereditary angioedema attacks with BW-20805, while plasma prekallikrein suppression remained substantial through Day 169.